Evaluation of Remnant Liver Function Using Primovist-enhanced MRI Before Resection/Ablation of Hepatocellular Carcinoma (LiFE)

Pre-Surgical Treatment or Radio Frequency Ablation (RFA) Evaluation of Future Remnant Liver Function Using Gd-EOB-DTPA Enhanced MRI in Patients Undergoing Hepatic Resection /RFA for Hepatocellular Carcinoma

The purpose of this study is to determine whether the global and segmental hepatic uptake and excretion of Gd-EOB-DTPA on Gd-EOB-DTPA-enhanced liver MRI correlates with standard liver function test results in the patients with Hepatocellular Carcinoma (HCC) before major hepatic resection or radiofrequency ablation (RFA).

Study Overview

• Status: Completed
• Conditions: Carcinoma, Hepatocellular; Liver Dysfunction
• Intervention / Treatment: Drug: Gd-EOB-DTPA; Drug: Gd-EOB-DTPA; Procedure: MRI; Procedure: MRI

Detailed Description

1. Preoperative/RFA assessment of remnant liver function is important for avoiding posthepatectomy liver failure. However, the function of the future remnant is decreased in patients with chronic liver disease or cirrhosis, compared to that of healthy patients with an equal volume. Therefore, volume-based estimation of hepatic reserve function is inadequate for patients with hepatic dysfunction.
2. Standard clinical liver function tests, such as ICG clearance rate or Child-Pugh score, provides measurements of the global hepatic function, but cannot evaluate the functional distribution in the liver. Gd-EOB-DTPA (Gadoxetic acid, Primovist®, Bayer Schering) enhanced MRI has been recently demonstrated to have the potential to be an imaging-based liver function test, with the possibility to detect functional differences on a regional or even segmental level.
3. Gd-EOB-DTPA-enhanced liver MRI may be able to assess not only global but also segmental liver function in patients with hepatocellular carcinoma (HCC) who have a relatively high risk for developing liver failure after surgical resection due to coexistent hepatic damage by chronic viral hepatitis and/or cirrhosis preoperatively.

The purpose of this study is to determine whether the global and segmental hepatic uptake and excretion of Gd-EOB-DTPA on Gd-EOB-DTPA-enhanced liver MRI correlates with standard liver function test results in the patients with HCC before major hepatic resection/RFA.

• Study Type: Observational
• Enrollment (Actual): 71

Contacts and Locations

Study Locations

• Korea, Republic of
  • Seoul, Korea, Republic of
    • Seoul National University Hospital
  • Seoul, Korea, Republic of
    • Asan Medical Center
  • Seoul, Korea, Republic of
    • The Catholic University of Korea, Seoul St. Mary's Hospital
  • Cheonnam Province
    • Hwasun-Gun, Cheonnam Province, Korea, Republic of
      • Cheonnam University Hwasun Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Group 1: Patients who will undergo hepatic resection/RFA for HCC. Group 2: Potential liver donors with normal hepatic function.

Description

Inclusion Criteria:

1. Patients with the diagnosis of HCC based on noninvasive diagnostic criteria of HCC proposed by 2010 AASLD
2. Surgical resection of hepatic resection greater than 2 Couinaud segments (including total hepatectomy for transplantation) or radiofrequency ablation is planned
3. Patients who provided the informed consent

Exclusion Criteria:

1. Patients younger than 18 yrs old
2. Patients who received hepatic surgery prior to this study
3. Patients who underwent TACE or RFA for greater than 2 segments within 3 months prior to this study
4. Patients who received radiation treatment including the liver or systemic chemotherapy
5. Patients who underwent contrast enhanced liver MRI within 3 days prior to this study
6. Patients with severe renal dysfunction (Cr .2.5 mg/dL or GFR < 30mL/min)
7. Patients with hypersensitivity to gadolinium
8. Patients with uncorrectable hypokalemia
9. Pregnant women, or reproductive age women who will not agree with contraception during this study period.
10. Patients with mental disorder which will interfere with voluntary agreement
11. Patients who have any contraindication to MRI (cardiac pacemaker, ferromagnetic implants, etc.)
12. Any other condition which, in the opinion of the Investigator, would make the patient unsuitable for enrollment or could interfere with the completion of the study.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Group 1: HCC resection/RFA; Patients who will undergo resection of at least two hepatic segments for HCC or radiofrequency ablation (RFA) for HCC and underwent gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI	Drug: Gd-EOB-DTPA; Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.; Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion.; Other Names: Gadoxetic Acid Disodium; BAY86-4873; Primovist/Eovist; Drug: Gd-EOB-DTPA; Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.; Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion.; Other Names: Gadoxetic Acid Disodium; BAY86-4873; Primovist/Eovist; Procedure: MRI; Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.; Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection.; Procedure: MRI; Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.; Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection.
Group 2: Potential liver donor; Potential liver donors with normal hepatic function and and underwent gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI	Drug: Gd-EOB-DTPA; Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.; Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion.; Other Names: Gadoxetic Acid Disodium; BAY86-4873; Primovist/Eovist; Drug: Gd-EOB-DTPA; Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.; Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion.; Other Names: Gadoxetic Acid Disodium; BAY86-4873; Primovist/Eovist; Procedure: MRI; Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.; Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection.; Procedure: MRI; Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.; Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Correlation of hepatic extraction fraction (HEF) of future remnant liver function (RLF) obtained from Gd-EOB-DTPA enhanced MRI with postoperative ICG R15 clearance test results	Predicted RLF (HEF mL) = the sum of the individual HEF of each voxel in future remnant segment	3 days (upto 5 days) after surgery

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Correlation of various functional and volumetric parameters derived from Gd-EOB-DTPA enhanced MRI and clinical liver function tests obtained before and after surgical resection	Functional parameters derived from Gd-EOB-DTPA enhanced MRI include hepatic extraction fraction [HEF], input-relative blood flow [irBF], hepatocellular uptake index [HUI], liver to spleen ratio (LSR).; Volumetric parameters include global liver volume and remnant liver volume.; Clinical liver function tests include ICG R15, MELD score and Child-Pugh score.; ICG R15 [Indocyanine green retention at 15 minutes, %] test will be performed within 3 days of preoperative MRI and 3 days after surgical resection.	within 7 days before, and 3 to 5 days after surgery
Analysis of clinical and MRI parameters of postoperative complication and morbidity	Clinical parameters refer to the following.Frequency of POD#5 days 50-50 criteriaEvaluation of operation related complicationIncidence of hepatic failure or death; Functional and volumetric MRI parameters of patients with postoperative complication and morbidity will be evaluated.; Correlation of MRI parameters with laboratory liver function tests.	upto 3 months (plus minus 1 week) after discharge
Exploratory analysis of MRI parameters and ICG R15 derived from potential liver donors	Correlation of functional parameters derived from Gd-EOB-DTPA enhanced MRI with ICG R15; Correlation of functional and volumetric parameters derived from Gd-EOB-DTPA enhanced MRI; Correlation of volumetric parameters derived from Gd-EOB-DTPA enhanced MRI and ICG15; Comparison of functional MRI parameters between potential liver donors and patients undergoing hepatic resection for HCC.	within 3 days of ICG R15 test

Collaborators and Investigators

• Sponsor: Seoul National University Hospital
• Collaborators: Bayer; Seoul St. Mary's Hospital; Asan Medical Center; Chonnam National University Hospital

Publications and helpful links

General Publications

• Yoon JH, Choi JI, Jeong YY, Schenk A, Chen L, Laue H, Kim SY, Lee JM. Pre-treatment estimation of future remnant liver function using gadoxetic acid MRI in patients with HCC. J Hepatol. 2016 Dec;65(6):1155-1162. doi: 10.1016/j.jhep.2016.07.024. Epub 2016 Jul 28.

Study record dates

Study Major Dates

• Study Start: December 1, 2011
• Primary Completion (ACTUAL): February 1, 2014
• Study Completion (ACTUAL): December 1, 2016

Study Registration Dates

• First Submitted: December 7, 2011
• First Submitted That Met QC Criteria: December 8, 2011
• First Posted (ESTIMATE): December 12, 2011

Study Record Updates

• Last Update Posted (ACTUAL): March 23, 2018
• Last Update Submitted That Met QC Criteria: March 22, 2018
• Last Verified: March 1, 2018

More Information

Terms related to this study

• Keywords: MRI; Hepatocellular Carcinoma; Hepatectomy; Liver Function Tests; Gd-EOB-DTPA
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Adenocarcinoma; Neoplasms, Glandular and Epithelial; Digestive System Neoplasms; Liver Neoplasms; Liver Diseases; Carcinoma; Carcinoma, Hepatocellular; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Protective Agents; Anticoagulants; Antidotes; Chelating Agents; Sequestering Agents; Iron Chelating Agents; Calcium Chelating Agents; Edetic Acid; Pentetic Acid
• Other Study ID Numbers: LIFE_ISS_2011

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO